ACE and Hyperkalemia: The incidence of hyperkalemia among patients prescribed ACE inhibitors or ARBs concomitantly with eplerenone was 1.1% and 0.8%, respectively, and that of patients without concomitant use of ACE inhibitors or ARBs was 0.6% and 0.5%, respectively.